The Latest in AML

Standard treatment lacking in relapsed refractory AML

October 22, 2020

AML

A uniquely patient-focused take on treating AML in older adults

October 13, 2020

AML

Survey quantifies COVID-19’s impact on oncology

September 20, 2020

AML maintenance: It’s now a thing

September 18, 2020

AML

FDA approves first maintenance therapy for AML

September 3, 2020

AML

Don’t overlook treating older patients with acute promyelocytic leukemia, expert says

July 17, 2020

AML

Combo drug improves survival in older patients with high-risk/secondary AML

June 26, 2020

AML

Venetoclax plus LDAC tops LDAC alone in AML

June 26, 2020

AML

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML

June 25, 2020

AML

First-in-kind anti-CD47 antibody shows promise for MDS and AML treatment

June 19, 2020

AML

VIALE-A confirms survival benefit for venetoclax-azacitidine in hard-to-treat AML

June 18, 2020

AML

Compound CAR T – a double whammy with promise for AML

June 15, 2020

Risk index stratifies pediatric leukemia patients undergoing HSCT

June 8, 2020

CD123 may be a marker for residual disease and response evaluation in AML and B-ALL

May 15, 2020

EHA webinar addresses treating AML patients with COVID-19

April 28, 2020